The plasma protein therapeutics market studied was projected to grow with a CAGR of nearly 5.3% over the forecast period. The major factor attributing to the growth of the market is the increasing prevalence of immune deficiency disorders, autoimmune disorders, neurological and bleeding disorders. In addition, the rise in geriatric population who are more prone to neurological disorders. Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth. The current happening research and development in the plasma protein segment are anticipated to drive its use through several applications. The expanding use of therapeutic protein drugs in the treatment of a broad range of clinical symptoms is expected to generate several growth opportunities for this market in forthcoming years. However, stringent regulations for the handling of plasma protein products, and lack of reimbursement policies are the drawbacks that hinder the market growth.
Scope of the Report
As per the scope of the report plasma protein therapy, treats distinct medical conditions, restoring missing or inadequate proteins found in plasma, to allow their receivers to lead healthier and more productive lives. The patients that rely upon plasma protein therapies generally require regular infusions for the duration of their lives. This report is segmented by product, by application, and by geography.
Key Market Trends
Albumin segment is expected to be the Fastest-Growing Segment over the Forecast Period
- Albumin is used to replenish blood volume loss resulting from trauma such as severe burns or an injury that causes blood loss. This medication is also used to treat low albumin levels caused by surgery, dialysis, abdominal infections, liver failure, pancreatitis, respiratory distress, bypass surgery, ovarian problems caused by fertility drugs, and other many other conditions.
- The major factor attributing to the growth of the market is increased awareness of plasma protein therapy. Furthermore, improved diagnosis of hypoalbuminemia caused by liver cirrhosis and hepatitis B is also a major factor driving the market growth. According to the National Pancreas Foundation, every year in the United States, nearly 220,000 people will be affected with acute pancreatitis, and more than 80,000 people will be diagnosed with chronic pancreatitis. Consistent with the statistics, as the incidence of the diseases that require albumin treatment increases, the market growth also increases.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall plasma protein therapeutics market, throughout the forecast period. The market growth is due to factors like increasing prevalence and incidence of autoimmune and neurological diseases. Increasing the geriatric population in this region also increases the patient pool like the old age people are more prone to neurological diseases. Furthermore, beneficial government initiatives, escalating awareness levels among the blood donors, existence of advanced protein fractioning procedures, greater per capita income in the developed countries, increase in the number of research partnerships are some of the drivers expected to increase the market growth in the region.
The plasma protein therapeutics market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Takeda Pharmaceutical Company Ltd, Octapharma USA Inc., Grifols, S.A., CSL Behring, Biotest AG, Baxter, and China Biologic Products Holdings, Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Autoimmune and Neurological Diseases
4.2.2 Rise in Research and Development in the Plasma Protein
4.3 Market Restraints
4.3.1 Strict Regulations for the Handling of Plasma Protein Products
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.3 Plasma Derived Factor Viii
5.2 By Application
5.2.2 Idiopathic Thrombocytopenic Purpura
5.2.3 Primary Immunodeficiencies
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
5.3.3 Asia Pacific
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Takeda Pharmaceutical Company Ltd.
6.1.2 Octapharma USA Inc.
6.1.3 Grifols, S.A.
6.1.4 CSL Behring
6.1.5 Biotest AG
6.1.7 China Biologic Products Holdings, Inc.
6.1.8 Kedrion S.p.A
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.